Prostate Cancer - Spain Drug Forecasts And Treatment Analysis To 2020

GlobalData analysis finds that the prostate cancer therapeutics market in Spain is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Prostate-Cancer--Spain-Drug-Forecasts-and-Treatment-Analysis-to-2020&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further.
In 2009, the Spain accounted for approximately 5% of the global prostate cancer therapeutics market.

In 2009, Taxotere was the leading drug for hormone refractory prostate cancer with approximate sales worth $17m and a market share of 11.5% of the prostate cancer therapeutics market in Spain. Leuprolide and Zoladex were the most used therapy for hormone dependent prostate cancer patients and accounted for 69.5% of the total prostate cancer therapeutics market in Spain. The impact of generic competition for Casodex in 2008 and Taxotere in 2011 is expected to partially offset the growth in revenue due to new products launched in the forecast period 2009 to 2020.

GlobalData, the industry analysis specialist, has released its new report, "Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the Spanish prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Spanish prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Spanish prostate cancer therapeutics market, highlighting the opportunity for future players.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Prostate-Cancer--Spain-Drug-Forecasts-and-Treatment-Analysis-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782